title: Do new cancer drugs offer good value for money? the perspective of oncologists, payers, patients, and general population.
authors.affiliation: Lilly S.A., Madrid, Spain.
authors.forename: T
authors.initials: T
authors.lastname: Dilla
authors.affiliation: Outcomes 10, Castellon, Spain.
authors.forename: L
authors.initials: L
authors.lastname: Lizán
authors.affiliation: Outcomes 10, Castellon, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Paz
authors.affiliation: Hospital Ramon y Cajal, Madrid, Spain.
authors.forename: P
authors.initials: P
authors.lastname: Garrido
authors.affiliation: Hospital Puerta de Hierro, Madrid, Spain.
authors.forename: C
authors.initials: C
authors.lastname: Avendaño
authors.affiliation: Hospital Clinico Universitario, Salamanca, Spain.
authors.forename: J J
authors.initials: JJ
authors.lastname: Cruz
authors.affiliation: Hospital La Paz, Madrid, Spain.
authors.forename: J
authors.initials: J
authors.lastname: Espinosa
authors.affiliation: Lilly S.A., Madrid, Spain.
authors.forename: J A
authors.initials: JA
authors.lastname: Sacristan